Michael Mark
Düsseldorf University Hospital(DE)Methodist Hospital(US)German Cardiac Society(DE)Heinrich Heine University Düsseldorf(DE)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Trauma and Emergency Care Studies, Metabolism, Diabetes, and Cancer, Patient Safety and Medication Errors
Most-Cited Works
- → CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis(2016)958 cited
- → Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors(2011)591 cited
- → SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition(2020)347 cited
- → Does gut hormone PYY3–36 decrease food intake in rodents?(2004)295 cited
- → 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes(2007)282 cited
- → PYY3‐36 as an anti‐obesity drug target(2005)121 cited